ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a potent, selective small molecule inhibitor of the transcription factor NRF2, with an IC₅₀ of 1.9 μM in cellular assays (APExBIO). NRF2 modulates antioxidant response, detoxification genes, and multidrug resistance in cancer, especially non-small cell lung cancer (NSCLC) (Zhou et al., 2024). ML385 downregulates NRF2-dependent gene expression in a dose- and time-dependent manner in A549 NSCLC cell lines. In vivo, ML385 reduces tumor growth and metastatic burden and enhances chemosensitivity to carboplatin. Its use has expanded to studies on ferroptosis, oxidative stress, and drug resistance in diverse disease models.

Biological Rationale

NRF2 (Nuclear factor erythroid 2-related factor 2) is a master regulator of cellular antioxidant defense. It controls the expression of genes involved in glutathione synthesis, detoxification, and drug efflux. High NRF2 activity confers cytoprotection under stress but also underlies chemoresistance in cancers such as NSCLC (Zhou et al., 2024). In alcoholic liver disease and cancer, NRF2 modulates the redox balance and ferroptosis, a form of iron-dependent cell death. Targeting NRF2 with selective inhibitors like ML385 allows researchers to dissect these pathways and evaluate therapeutic vulnerabilities.

Mechanism of Action of ML385

ML385 selectively inhibits NRF2 by blocking its transcriptional activity. It binds to the Neh1 DNA-binding domain of NRF2, preventing the activation of downstream antioxidant response elements (AREs) (APExBIO). This results in the suppression of NRF2-dependent genes, including those coding for glutathione S-transferases, NAD(P)H quinone dehydrogenase 1 (NQO1), and multidrug resistance proteins. ML385 does not significantly inhibit related transcription factors at effective concentrations (IC₅₀ 1.9 μM). Its effect is dose- and time-dependent in vitro and has been validated in A549 (NSCLC) and other cell lines.

Evidence & Benchmarks

• ML385 inhibits NRF2 activity with an IC₅₀ of 1.9 μM in A549 human NSCLC cells (APExBIO).
• In NSCLC mouse models, ML385 (100 mg/kg/day, intraperitoneal) reduces tumor growth and metastasis (Zhou et al., 2024).
• Combining ML385 with carboplatin enhances chemosensitivity and reduces tumor burden in vivo (Zhou et al., 2024).
• ML385 is insoluble in water and ethanol but dissolves at ≥13.33 mg/mL in DMSO (room temperature, neutral pH) (APExBIO).
• ML385 downregulates antioxidant and multidrug transporter gene expression, decreasing NRF2 protein and target mRNA levels within 24 hours in cell-based assays (Zhou et al., 2024).
• In alcoholic liver disease models, ML385 blocks the protective effect of NRF2-activating polysaccharides, confirming its on-target activity (Zhou et al., 2024).

This article extends the practical workflow guidance found in Solving NRF2 Pathway Challenges in Cancer Research with ML385 by providing new, peer-reviewed benchmarks from recent in vivo models. It also clarifies the translational context compared to ML385: Selective NRF2 Inhibitor for Cancer Research Workflow, which focuses on cell-based protocols.

Applications, Limits & Misconceptions

ML385 is primarily used to:

• Study NRF2’s role in cancer, especially NSCLC and drug-resistant phenotypes.
• Investigate oxidative stress mechanisms in liver disease, ferroptosis, and inflammation.
• Model and overcome therapeutic resistance in combination with chemotherapeutics (e.g., carboplatin).

It is a standard in cancer therapeutic development and oxidative stress modulation workflows (Zhou et al., 2024).

Common Pitfalls or Misconceptions

• ML385 is not effective in NRF2-null or KEAP1-mutant cell lines lacking NRF2 activity.
• It is not a generic antioxidant or ROS scavenger; its effects are NRF2-dependent.
• ML385 is not soluble in aqueous or ethanol solutions; improper solvents compromise its activity.
• Long-term storage of ML385 solutions at room temperature or >-20°C reduces stability and efficacy.
• ML385 does not inhibit unrelated transcription factors or non-NRF2-mediated oxidative stress pathways at recommended concentrations.

Workflow Integration & Parameters

ML385 (SKU B8300) from APExBIO should be dissolved in DMSO to a stock concentration of at least 13.33 mg/mL. Working solutions are freshly diluted in cell culture medium or injection buffer immediately before use. For in vitro assays, typical concentrations range from 0.5–10 μM, with exposure times from 6–48 hours depending on the endpoint. In vivo, doses up to 100 mg/kg/day (i.p.) are validated in mouse NSCLC and liver injury models (Zhou et al., 2024). ML385 is stable at -20°C as a solid for long-term storage; avoid repeated freeze-thaw cycles of solutions.

Researchers integrating ML385 in workflows can refer to ML385: Selective NRF2 Inhibitor for Cancer Research Excellence for experimental design strategies, while this article provides updated in vivo and translational benchmarks.

Conclusion & Outlook

ML385 is a robust, selective tool for modulating NRF2 activity in cancer, liver disease, and redox biology. It enables clear resolution of NRF2-dependent mechanisms underpinning therapeutic resistance and oxidative damage. With growing interest in ferroptosis and combination therapy, ML385’s validated performance in preclinical models will continue to support translational research. For further details and best practices, consult the official APExBIO ML385 product page.